Background/Aims: The Kunitz Protease Inhibitor (KPI) domain of protease nexin 2 (PN2) potently inhibits coagulation factor XIa. Recombinant KPI has been shown to inhibit thrombosis in mouse models, but its clearance from the murine circulation remains uncharacterized. The present study explored the pharmacokinetic and pharmacodynamic effects of fusing KPI to human serum albumin (HSA) in fusion protein KPIHSA. Methods: Hexahistidine-tagged KPI (63 amino acids) and KPIHSA (656 amino acids) were expressed in Pichia pastoris yeast and purified by nickel-chelate chromatography. Clearance profiles in mice were determined, as well as the effects of KPI or KPIHSA administration on FeCl 3 -induced vena cava thrombus size or carotid artery time to occlusion, respectively. Results: Fusion to HSA increased the mean terminal half-life of KPI by 8-fold and eliminated its interaction with the low density lipoprotein receptor-related protein. KPI and KPIHSA similarly reduced thrombus size and occlusion in both venous and arterial thrombosis models when administered at the time of injury, but only KPI was effective when administered one hour before injury. Conclusions: Albumin fusion deflects KPI from rapid in vivo clearance without impairing its antithrombotic properties and widens its potential therapeutic window.
tissue factor/FVII(a), FIX, and FX, converts FXI to the active serine protease FXIa [1] [2] [3] . FXIa activates FIX, providing additional procoagulant impetus when physiological hemostasis must be restored [4] . Neither patients [5] nor mice [6] with genetic deficiency of FXI bleed spontaneously, but instead acquire resistance to thrombosis [7] [8] [9] . For these reasons, FXI(a) has become a target for drug development [10] . Although an antisense oligonucleotide agent that reduces FXI mRNA levels and circulating FXI to ~30% of normal, indirectly affecting FXIa concentrations, has been shown to be effective in preventing thrombotic complications after knee replacement [11] , efforts to develop agents that directly inhibit FXIa remain at the pre-clinical stage.
Natural physiological inhibitors of FXIa include the serpins protein Z-dependent inhibitor [12] , α 1 -proteinase inhibitor [13] , C 1 -inhibitor [14] , protease nexin 1 [14] , antithrombin [15] , and α 2 -antiplasmin [14] . These inhibitors demonstrate a wide range of rates of inhibition typically requiring glycosaminoglycans for maximal activity; none inhibit FXIa exclusively or preferentially [14] . In contrast, FXIa is also inhibited in a glycosaminoglycan-independent manner by the Kunitz family inhibitor, protease nexin 2 (PN2) [16] [17] [18] . PN2 is an isoform of the amyloid precursor protein (β-APP) that is secreted from the α-granules of activated platelets [19] and which inhibits its primary target, FXIa, 40-to 500-fold more rapidly than secondary target proteases plasmin, FIXa, FXa, FVIIa/tissue factor, and kallikrein [20] .
The anti-FXIa inhibitory domain of PN2 is comprised entirely of the 57 contiguous amino acids located between Glu 289 and Ile 345 of PN2, which form its Kunitz Protease Inhibitor (KPI) domain [21, 22] . Co-crystals of recombinant KPI and the catalytic domain of FXIa revealed that it binds the active site of the protease [23] . Recombinant KPI has been shown to reduce the rate of vascular occlusion or the infarct volume in ferric chloride-induced models of carotid or cerebral artery thrombosis [24] , but its clearance rates have not been previously established or modified. We sought to extend the circulatory half-life of KPI by fusing it to human serum albumin.
Materials and Methods
Expression and purification of albumin fusion protein KPIHSA Oligodeoxyribonucleotide primers (see Table 1 for sequences) were synthesized by MOBIX Lab (McMaster University central facility, Hamilton, ON, Canada). All DNA amplifications used Phusion heatstable DNA polymerase according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA, USA). DNA sequences encoding KPI, appropriate for in-frame fusion to a human serum albumin (HSA) cDNA, were assembled using two sequential PCR steps. First, primers PrPKI-1 and ML-08-6225 were used to amplify plasmid pPICZ9ssHV3HSAH6 [25] , yielding a 1243 bp product. Following gel purification, this DNA product was amplified again, substituting PrKPI-2 for PrPKI-1. The second 1339 bp amplification product was restricted with XhoI and XbaI and inserted between these sites in pPICZ9ssHSAH 6 [25] , yielding pPICZ9ssKPIHSAH 6 . This plasmid contained an open reading frame combining the 80 amino acid prepro-α factor secretory signal sequence (ss), the 57 amino acid KPI domain, a Gly 6 SerMet spacer, the 584 codons of mature HSA, and a C-terminal hexahistidine tag to facilitate purification. Plasmid pPICZ9ssKPIHSAH 6 was employed to transform Pichia pastoris strain X-33 to Zeocin resistance, transformed cell lines were cultured and induced with methanol, and secreted protein KPIHSA was purified from conditioned media using nickel-chelate affinity chromatography, as previously described [25] .
Expression and purification of KPI
To generate a P. pastoris expression plasmid directing the expression of unfused KPI, PCR was performed using plasmid pPICZ9ssKPIHSAH 6 as the template and primers PrKPI-1 and Pr3. The 360 bp amplification product was restricted with XhoI and EcoRI and the 204 bp restriction product was restricted with, and inserted between, these sites in pPICZ9ssamp [26] to yield pPIC9zssKPIH 6 . This plasmid was used exactly as described above for pPICZ9ssKPIHSAH 6 in directing the expression and purification of recombinant KPI (63 amino acids), comprising the 57 amino acids of KPI and a C-terminal hexahistidine tag.
Expression and purification of GST and RAP
A cDNA encoding human low density lipoprotein receptor-related protein associated protein 1 (LRPAP1, RAP) was purchased from Sino Biological (Beijing, China) and modified by PCR as described above using Pr4 and Pr5. The resulting amplification product was restricted with NcoI and EcoRI and inserted between these sites in pBAD to yield pBAD-RAP, which was used to transform E. coli Top10 cells to ampicillin resistance. RAP was purified by nickel-chelate chromatography of bacterial lysates following induction of expression with 0.002% arabinose. Glutathione sulfotransferase (GST) was purified from cultures of E. coli Top10 transformed with pGEX5P and induced with 0.1 mM isopropylthiogalactoside, using affinity chromatography on glutathione-Sepharose as previously described.
Mass spectrometry
A sample of 2.5 mg/ml purified recombinant KPI in sterile double-distilled water was diluted 1:10 in 0.5% formic acid/50% acetonitrile and subjected to time-of-flight (TOF) mass spectrometry using electrospray ionization (ESI) for molecular mass determination by mass spectrometry (ESI/MS) using a Micromass Global Q-TOF Ultima instrument housed at the McMaster Regional Centre for Mass Spectrometry service facility of McMaster University.
Inhibition of protease-mediated amidolysis by KPI and KPIHSA
The velocity of amidolysis of chromogenic substrate S2366 (Instrumentation Laboratory (Lexington, MA, USA) by FXIa was determined using 96-well flat bottom microtiter plates (Immunulon IV, Thermo Fisher Scientific) at 37°C in 20 mM sodium phosphate pH 7.4, 0.1% (w/vol) polyethylene glycol 8000, 100 mM sodium chloride, and 0.1 mM disodium ethylenediaminetetraacetic acid, using wavelength 405 nm and an ELx808 Absorbance Microplate Reader (Biotek, Winooski, VT, USA). Reactions contained 1nM FXIa, 0 to 2500 mM S2336, and 0 to 20 nM KPI or KPIHSA. Analogous experiments containing factor VIIa (FVIIa) in the presence of tissue factor (TF), factor IXa (FIXa), factor Xa (FXa), or plasmin were conducted using chromogenic substrates Spectrozyme FVIIa and Spectrozyme FIXa (Sekisui Diagnostics GmbH) and S2222 (FXa) and S2251 (plasmin) (Chromogenix). Purified proteases, as well as TF, were purchased from Enzyme Research Laboratories. Inhibitory constants (K i ) for the inhibition of all proteases by KPI or KPIHSA were determined from non-linear fit for competitive inhibition of velocity versus substrate plots using GraphPad Prism (GraphPad Software, San Diego, CA, USA).
I-labelling of KPI proteins and in vivo clearance studies
Purified recombinant KPI, KPIHSA, or HSA, all produced in C-terminally hexahistidine-tagged forms in the P. pastoris system, as well as human fibrinogen (Enzyme Research Laboratories) were separately iodinated using the Iodogen (Thermo Fisher Scientific) method [27] , using sodium 125 I. Radiolabelled protein preparations were dialyzed exhaustively against phosphate-buffered saline. All in vivo experiments in this study employed CD1 mice (Charles River, Wilmington, MA, USA) and were approved by the Animal Research Ethics Board of the Faculty of Health Sciences, McMaster University. For clearance studies, mice were injected intravenously with 1 X 10 7 cpm protein-bound KPI, KPIHSA, or HSA, and serial blood samples were taken from the tail vein over time. Acid-bound radioactivity was determined from serial plasma samples. Initial and terminal half-lives were determined using a two compartment model and curve-stripping as previously described [28, 29] . In some experiments radiolabelled protein preparations were combined with purified RAP or GST (0.15 mM final concentration) prior to injection, as previously described [30] . In others, mice were separately injected with 6 X 10 6 cpm protein-bound KPI, KPIHSA, or HSA, and were sacrificed 30 minutes later. Specific organs were excised post-mortem, rinsed in ice-cold saline, and organ-associated radioactivity was determined by g-counting in a Packard Cobra II counter.
Ferric chloride-treated murine vena cava thrombosis model
Thrombus formation was induced by topical application of 10% (w/vol) FeCl 3 on the surgically exposed murine vena cava. Mice were anesthetized with 1.5% isoflurane, the vessel exposed, and recombinant protein (12.7 nmol KPI (90 µg/mouse) or KPIHSA (940 µg/mouse, respectively) or saline vehicle was injected intravenously 2 or 60 minutes prior to application of the FeCl 3 -saturated filter paper to the vessel, for 3 minutes. Thirty minutes after removal of the filter paper, clots were excised and g-counted to determine their content of 125 I-fibrin and ( 125 I-fibrinogen ( 125 I-fibrin(ogen)) by g-counting as described above [31, 32] .
Occlusion of ferric chloride-treated murine carotid arteries
The time to occlusion (TTO) of surgically exposed murine carotid arteries was determined by following arterial blood flow with a Doppler ultrasound flow meter and a 0.5 mm diameter flow probe (Transonic Systems, Ithaca, NY, USA), following application of FeCl 3 -saturated filter paper, and determining the earliest time point at which blood flow was reduced to less than 0.10 mL/minute. Filter paper and recombinant protein administration timing was the same as that used in in the vena cava model above. Vessels not occluding during the 60 minute observation period had their TTO recorded as 60 minutes. Anesthetic cover in these experiments was provided by intraperitoneal injection of 0.3 ml 2.5% tribromoethanol per mouse.
Statistics
Data is given as the mean ± the standard error of the mean (SEM). Statistical analysis was facilitated using GraphPad InStat (GraphPad software). A p value of < 0.05 was taken to indicate statistical significance. For multiple comparisons, data were assessed using ANOVA with post-tests; data sets departing from normal distribution or with dissimilar standard deviations were logarithmically transformed to meet these ANOVA pre-conditions. Paired comparisons employed a two-tailed, unpaired t test, Welch corrected. Additional details are provided in the text and/or figure legends.
Results
To test whether albumin fusion extended the circulatory half-life of KPI, we designed two recombinant proteins: KPI; and KPIHSA. Both proteins were designed to terminate in a C-terminal hexahistidine tag, for ease of identification and purification, while KPIHSA contained a hexaglycine spacer to provide some spatial separation between the folded fused proteins. The orientation and predicted length of each protein is shown in Fig. 1A , as well as that of previously described recombinant HSA made in the same expression system (HSA, HSAH 6 ).
Induction of cultures of Pichia pastoris transformed with plasmids specifying the secretion of KPIHSA (Fig. 1B) or KPI (Fig. 1C) led to the appearance of novel 74 kDa and 12 kDa polypeptide species in conditioned media that increased in intensity on stained polyacrylamide gels over 24 to 96 hours. Both putative KPI-related proteins were purified using nickel affinity chromatography that enriched only these major species (Fig. 1D) . The putative fusion protein, like recombinant HSA, but not the putative unfused KPI, reacted with anti-HSA antibodies on immunoblots (Fig. 1E) ; both putative KPI-related proteins reacted with anti-hexahistidine antibodies (data not shown). Positive identification of these proteins was provided by their acting as high affinity competitive inhibitors of FXIamediated amidolysis of S2366, as indicated in the Lineweaver-Burke plots shown in Fig. 1F and 1G. K i values of 7 ± 1 nM for KPI and 15 ± 2 nM for KPIHSA (n=4, mean ± SEM) were obtained by analysis of these data (Table 2) ; the difference was statistically significant (p = 0.034 by unpaired t test, Welch corrected). The addition of 5 units/mL standard heparin to kinetic reactions such as those shown in Fig 1F and 1G containing 20 nM KPI or KPIHSA had no effect (data not shown). Because KPI migrated less rapidly on SDS-PAGE in our hands than expected, we verified its mass by ESI/MS; the major peak in the resulting spectrum had a deconvoluted mass of 7090 atomic mass units, a value highly similar to the predicted molecular mass of 7096 Daltons for KPI.
Having noted a 2-fold difference in the K i values for inhibition of FXIa by KPI versus KPIHSA, we next compared the kinetics of enzyme inhibition of the two forms of KPI for other serine proteases. As expected, K i values for inhibition of these other proteases by KPI were increased 14-to 340-fold over the corresponding values for inhibition of FXIa. However, in contrast to the results obtained with FXIa, no significant difference was found between the K i values for KPI versus those of KPIHSA for FVIIa, FIXa, FXa, or plasmin inhibition ( Table 2) .
The clearance profile of KPI in mice diverged from that of KPIHSA or HSA within minutes of injection ( Fig. 2A and 2B) ; after 30 minutes, only 17 ± 1% of the initial dose of KPI remained in the circulation, significantly less than either KPIHSA (77 ± 2%, p < 0.05 vs. KPI) or HSA (80 ± 2%, p < 0.01 vs. KPI) (n=6-12), which did not differ between themselves. The same order of protein clearance (KPI>>KPIHSA=HSA) was apparent at 6 hours post-injection (Fig. 2C) , while by 24 hours post-injection the more rapid clearance of KPIHSA than HSA had become statistically significant (KPI>>KPIHSA>HSA). Resolution of clearance curves using a two compartment model was used to calculate initial (α) and terminal (β) half-lives, as shown in Table 3 . Fusion to albumin significantly prolonged the mean t 1/2 α of KPI 8.5-fold, but KPIHSA remained 2.3-fold more rapidly cleared than HSA. Similarly, the mean t 1/2 β of KPI was significantly prolonged 6.5-fold via fusion, but it remained 1.1-fold less rapidly cleared E. The percentage of the protein-bound radioactive dose recovered 2 minutes post injection for KPI (left columns) or KPIHSA (right columns) co-injected with control protein GST (CON, black bars) or RAP (white bars) is shown (arithmetic means ± SEM, n=6). *** (p<0.001) indicates significant difference between the groups (identified on the x axis) linked by horizontal lines (ANOVA). F. The percentage of the total radioactive dose recovered 30 minutes post-injection for KPI (grey bars), KPIHSA (white bars), or HSA (black bars) is shown for each of five organs identified on the x axis (arithmetic means ± SEM, n=6). ** (p<0.01) and *** (p<0.001) indicates significant difference between the groups, for liver or kidney, for groups at the outer limits of the horizontal lines above the graphs (ANOVA). Only data from organs with >1% KPI distribution (liver and kidneys) were evaluated statistically. Five organ samples were taken from each mouse of groups of six. Recombinant RAP was produced in a bacterial expression system and purified to near homogeneity, as was unrelated control protein GST (Fig. 2D, upper  panel) ; RAP, but not GST, reacted with anti-hexahistidine antibodies due to the planned presence of a hexahistidine tag in the former, but not the latter protein (Fig. 2, lower panel) . Recovery of injected radiolabelled protein two minutes after injection was significantly greater for KPI, but not KPIHSA, following administration of RAP than following administration of an identical dose of control protein GST (Fig. 2E ). Fusion to albumin changed not only the clearance behaviour of KPI but also its organ distribution (Fig. 2F) . Of five organs sampled 30 minutes post-injection, KPI was predominantly found in the kidneys, to a significantly (1.9-fold) greater extent than KPI; this differential localization was even more pronounced with respect to HSA (4.1-fold). Fusion to albumin also significantly redirected KPI to the liver, as evidenced by the detection of 2.9-fold more KPIHSA than KPI in that organ, versus 3.2-fold more HSA (both changes significant).
The effectiveness of KPI and KPIHSA as antithrombotic agents was tested in vivo in anesthetized mice with surgically exposed carotid arteries (Fig. 3A or 3B ) or vena cava ( Fig.  3C and 3D ) treated with ferric chloride. Both KPI-related proteins significantly prolonged the time to arterial occlusion (Fig. 3A) or decreased the size of the venous clot (Fig. 3C ) when administered two minutes prior to induction of thrombosis, at equimolar doses, versus saline vehicle controls. However, when the time between recombinant protein administration and induction of thrombosis was increased to 60 minutes, KPI lost its antithrombotic activity in either arterial or venous models, while KPIHSA continued to exert its antithrombotic effects in both settings (Fig. 3B and 3D) .
Discussion
The present study tested two hypotheses: that KPI would exhibit rapid in vivo clearance from the circulation after injection; and that fusion of KPI to HSA would increase its circulatory half-life and duration of antithrombotic action. With respect to the first hypothesis, and as predicted by Wu et al [24] ., KPI was rapidly removed from the murine circulation after intravenous injection. KPI clearance resembled that of other small proteins less than 80 amino acids in length such as hirudin [25, 35] or barbourin [36] , which are characterized by rapid renal losses without reabsorption. Specifically with respect to recombinant hexahistidine-tagged hirudin variant 3 (HV3), we previously noted that ~90% I-fibrinogen found in murine vena cava clots following treatment with ferric chloride and with agents identified on the x axis 2 minutes prior to injury. Bars are arithmetic means ± SEM (n=9). D. As in C, but treated with agents 60 minutes prior to injury. * (p<0.05), ** (p<0.01), *** (p<0.001) indicate significant difference between the groups (identified on the x axis) linked by horizontal lines (ANOVA). Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry of the radiolabeled dose was lost from the murine circulation within one hour of injection, a profile highly similar to that we observed for KPI in the current study [25] . Fusion to albumin slowed both the rapid and slower phases of KPI's biphasic clearance by 6.5-to 8.5-fold, providing a clear pharmacokinetic enhancement. The prolongation of KPI residence time in the circulation afforded by albumin fusion also correlated with prolonged antithrombotic action. Administration of KPI one hour before induction of thrombosis eliminated its antithrombotic effects, consistent with its expected disappearance from the circulation. KPI had previously been demonstrated to reduce the size of carotid artery thrombi or ischemic brain damage arising from occlusion of the middle cerebral artery in mice, either in isolated form [24] or when present in PN2 [37] . Our results are therefore consistent with these previous findings and extend them into the venous thrombosis setting. Although fusion to albumin prolonged the rate of KPI clearance, it did not equalize it to that of recombinant HSA in mice. There are at least two potential explanations for this observation. Albumin fusion is thought to extend clearance of fused proteins by deflection from glomerular filtration and through recycling after endocytosis mediated by the neonatal Fc receptor (FcRn) [38] . A fusion protein could fail to acquire the full, slowly cleared phenotype of albumin due either to retention of binding sites for clearance receptors or by obscuring the FcRn binding sites on albumin by steric hindrance or allosteric effects [39] . KPI cleared less rapidly when co-injected into mice with the LRP antagonist RAP, but RAP had no significant effect on KPIHSA clearance when co-administered with the fusion protein.
It therefore seems more likely that the attachment of KPI to HSA obscured some determinant on the HSA surface partially mediating FcRn-dependent recycling. HSA has three domains, and mutagenic studies using one-or two-domain recombinant fragments of HSA have shown a principal human FcRn binding site in C-terminal domain III, but also some contribution of N-terminal domain I [40] . The latter region might be affected by attachment of KPI to the N-terminus of recombinant HSA. It should be noted that HSA is not recognized as effectively by murine FcRn as murine serum albumin, and this incompatibility contributes to the shorter half-life of HSA in mice than in humans [41] . Andersen et al. found a terminal halflife for HSA in mice of 21 hours, compared to 11 hours in this study; both values fall far short of the 19 day half-life of HSA in humans [40] . The comparatively minor difference between the two HSA observed half-lives in mice could have arisen due to differences in detection methods (unlabelled or radiolabelled), expression systems (Saccharomyces cerevisiaie or Pichia pastoris), or affinity tags (myc epitope or hexahistidine).
Fusion of KPI to HSA not only conferred the bulk of HSA's slowly cleared phenotype on KPI, it also left most of the affinity of KPI for FXIa intact in KPIHSA. This retention was demonstrated by the minor 2.1-fold increase in K i of KPIHSA for FXIa compared to that of KPI. K i values for other serine proteases less rapidly inhibited by KPI (e.g. plasmin) were unaffected by albumin fusion. Co-crystallization of KPI with the catalytic domain of FXIa revealed tight contacts between two KPI loops (residues 11-20 and 34-38) linked by a disulphide bond between Cys14 and Cys38: 11TGPCRAMISR20 (P5-P5′); and 34FYGGC38 [23] . The C-terminus of KPI is freely accessible in the structure, suggesting that the minor reduction in affinity of KPIHSA for FXIa likely arises from conformational changes transmitted through the KPI chain, as opposed to steric hindrance involving possible clashes between the HSA moiety of the fusion protein and FXIa. It is also possible that this effect could be minimized by optimization of the hexaglycine spacer found between the KPI and HSA domains of KPIHSA; previous improvements to the activity of a coagulation factor IX HSA fusion protein were achieved by substituting a longer spacer for a shorter one [42] . The K i of recombinant KPI for FXIa has previously been reported as 0.45 nM, substantially lower than determined in this study, but that form of KPI differed from that we employed in containing three additional PN2 residues, lacked a hexahistidine addition, and was assessed kinetically using different methodology [43] .
Our in vitro results confirm previous observations that KPI is not absolutely specific for FXIa, and extend them by showing that this inhibitory profile is mirrored in fusion protein KPIHSA. The ability of both KPI and KPIHSA to inhibit other coagulation proteins raises the [44] ; assuming that similar amounts of activated coagulation proteins are generated in vivo in each case in clot formation, KPI would inhibit FXIa long before having an effect on the other two proteases. The same logic applies to FVIIa, but to a greater extent, in that the plasma concentration of zymogen FVII is 10-to 20-fold lower than that of FXI, FX, or FIX. Secondly, of the tested proteases, plasmin is the closest second to FXIa with respect to its speed of inactivation by KPI or KPIHSA. If KPI inhibited plasmin it would promote thrombus formation or thrombotic occlusion, not counteract these processes. Thus, even in the unlikely event that KPI or KPIHSA significantly inhibit plasmin in vivo, this would not negate the primary effect of these proteins as FXIa inhibitors. Current interest in inhibiting FXIa is high [10] . To date, the only anti-FXI strategy that has been tested in clinical trials is reduction of FXI mRNA and protein via antisense oligonucleotide administration [11] . In preclinical models, several small peptidomimetic candidate drugs and several anti-FXI monoclonal antibodies have shown some promise as antithrombotic agents [45] . KPI is a human polypeptide, naturally occurring within the context of soluble, non-amyloidigenic isoforms of PN2 (also known as the amyloid precursor protein), that would not be expected to be immunogenic or toxic. Here we have demonstrated that KPI linked to HSA, a human polypeptide with an excellent safety profile, both as a stand-alone drug and as a fusion partner, retains its efficacy as an antithrombotic agent in a prolonged manner. In mice, KPI demonstrates a clearance profile with and without HSA fusion very similar to that of hirudin variant 3. We found an approximate 10-fold extension of terminal half-life of HV3in mice for HV3HSA fusion protein [25] and a 160-fold extension in rabbits for a homologous HV3-rabbit serum albumin fusion protein [35] . It is therefore likely that KPIHSA will demonstrate even larger increments in circulatory half-life in nonmurine systems.
One limitation of our study is that we lacked the opportunity or resources to test KPIHSA in a genetically engineered mouse model in which the β-APP gene has been ablated [46] . β-APP knockout mice were shown to exhibit a significant, ~25% reduction in TTO of carotid arteries treated with Rose Bengal dye and laser light. Based on our results in this study, we predict that either KPI or KPIHSA would restore TTO to wild-type levels if provided at doses similar to those we employed in the FeCl 3 -treated carotid artery thrombosis model in sufficiently powered experiments.
Conclusion
KPIHSA could therefore be used in both murine and non-murine animal models to explore further the pathophysiological consequences of FXIa inhibition, and could one day join the ranks of clinically employed HSA fusion proteins, such as those engineered with coagulation factor IX and glucagon-like peptide-1 agonist partners.
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